WeightlessnessVIVALDI2NCT05493176
A 5-day Dry Immersion Study on 20 Healthy Male Volunteers
A study testing Dry immersion in people with Weightlessness, run by Centre National d'Etudes Spatiales at 1 site in France.
Trial summary
Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity. Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Read more about this study
- Who is it for?
- Ages 20 to 40 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Weightlessness
- What is being tested?
- Dry immersion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 23 Aug 2022to 24 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male volunteer (see below the description of medical tests and laboratory analysis performed at the selection visit),
- Age 20 to 40,
- No overweight nor excessive thinness with BMI (weight Kg/ height m2) between 20 and 26,
- Height between 158cm and 185 cm,
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any chronic disease or any acute infectious disease or cardiovascular, neurological, ear, nose, and throat (ENT) (especially orthostatic hypotension and vestibular disorders), orthopaedic or musculoskeletal disorders,
- Fitness level assessment: 35 ml/min./kg < VO2max < 55 ml/min./kg,
Show all 11Show fewer
- Non active smokers,
- No alcohol, or drug addiction, and no medical treatment,
- Covered by a Health Insurance System,
- Having signed the informed consent,
- Free from any engagement during the study.
Who cannot join
- Any history or presence of clinically relevant cardiovascular, neurological or ENT (especially orthostatic hypotension and vestibular disorders), any chronic disease; any acute infectious disease, in particular
- Symptomatic orthostatic hypotension whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure (SBP) equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position,
- Cardiac rhythm disorders,
- Hypertension,
- Chronic back pains,
- Vertebral fracture, scoliosis or herniated disc,
Show all 37Show fewer
- Glaucoma,
- Self-reported hearing problems,
- History of migraines,
- History of hiatus hernia or gastro-esophageal reflux,
- History of thyroid dysfunction, renal stones, diabetes,
- History of head trauma,
- History of genetic muscle and bone diseases of any kind,
- Past records of thrombophlebitis, family history of thrombosis or positive response in thrombosis screening procedure (anti thrombin III, S-protein, C-protein, factor V Leiden mutation and the mutation 20210 of the prothrombin gene),
- Signs of venous insufficiency, varicose veins, or telangiectasia
- Bone mineral density: T-score ≤ -1.5,
- Poor tolerance to blood sampling,
- Having given whole blood (more than 7ml/kg) in a period of 8 weeks or less before the start of the experiment, or having given whole blood more than 5 times in the past 12 months,
- Significant history of allergy, especially no dermatological allergy,
- History of food allergy,
- Significant anomaly detected in the biological analysis,
- Positive reaction to any of the following tests: IgM antibodies for the Hepatovirus A (HVA IgM), Hepatitis B surface antigen (HBsAg), anti-Hepatovirus C antibodies (hepatitis C), antibodies to human immunodeficiency virus type 1 and 2,
- Vegetarian or vegan,
- Refusal to give permission to contact his general practitioner,
- Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development,
- Subject already participating or in the exclusion period of a clinical research,
- Subject who has received more than 4500 Euros within 12 months for being a research subject,
- Subject who cannot be contacted in case of emergency,
- MRI contraindications History or active claustrophobia, Osteosynthesis material, presence of metallic implants or any other contra-indication for MRI, Allergy to Gadolinium.
- Vulnerable persons according to law "Code de la Santé Publique" (L1121-5 to L1121-8) :
- Pregnant women (urine pregnancy test performed at the selection visit and on the day of arrival in the facility),
- Women during childbirth and breastfeeding mothers,
- Persons deprived of their liberty by an administrative or judicial decision,
- Persons under involuntary psychiatric care,
- Persons admitted in a health or social establishment for purposes other than research,
- Minors,
- Adults subject to legal protection (subject under guardianship or trusteeship) or unable to express their consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Standardization of the Dry Immersion Model Used as a Ground-based Model to Mimic Weightlessness. Phase 2: a 5-day Dry Immersion Study on 20 Healthy Male Volunteers (VIVALDI2)
Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity. Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Within a relatively short duration, the model can faithfully reproduce most physiological effects of actual microgravity, including centralization of body fluids, support unloading, and hypokinesia.
The main objective of the present study is to investigate the physiological effects of 5 days of dry immersion in 20 healthy male subjects, and to obtain DI-in-Men Reference Dataset. A set of measurements will assess the changes in the cardiovascular, neuro-ophthalmological, hematological, metabolic, sensorimotor, immune, muscle and bone systems.
Read the detailed description
Space flights have shown the possibilities and limitations of human adaptation to space. For the last 50 years, results have shown that the space environment and microgravity in particular, cause changes that may affect the performance of astronauts. These physiological changes are now better known: prolonged exposure to weightlessness can lead to significant loss of bone and muscle mass, strength, cardiovascular and sensory-motor deconditioning, immune, hormonal and metabolic changes .
Moreover, recently a new suite of physiological adaptations and consequences of space flight has been acknowledged. Indeed, after long flights, some astronauts present persistent ophthalmologic changes, mostly a hyperopic shift, an increase in optic nerve sheath diameter and occasionally a papillary oedema now defined by National Aeronautics and Space Administration (NASA) as Spaceflight-Associated Neuro-ocular Syndrome (SANS). Some of these vision changes remain unresolved for years post-flight. This phenomenon has most likely existed since the beginning of human space flight but is just recently being recognized as a major consequence of adaptation to microgravity.
Overall, spaceflight induces physiological multi-system deconditioning which may impact astronauts' efficiency and create difficulties upon their return to normal gravity. Understanding the underlying mechanisms of these processes and developing efficient countermeasures to prevent, limit or reverse this deconditioning remain important challenges and major priorities for manned space programs.
The space agencies are actively engaged in studying the physiological adaptation to space environment through studies on board the International Space Station (ISS) but also on the ground. Indeed, considering the limited number of flight opportunities, the difficulties related to the performance of in-flight experiments (operational constraints for astronauts, limited capabilities of in-flight biomedical devices), ground-based experiments simulating the effects of weightlessness are used to better understand the mechanisms of physiological adaptation, design and validate the countermeasures. Different methods are used to simulate microgravity on Earth. However, two approaches, -6° head-down bed rest (HDBR) and dry immersion (DI) have provided possibilities for long-term exposures with findings closest to those seen with a weightless state. They produce changes in body composition (including body fluid redistribution), cardiovascular and skeletal muscle characteristics that resemble the effects of microgravity.
The common physiological denominator is the combination of a cephalad shift of body fluids and reduced physical activity. Being similar in their effects on the human body, these models, however, differ in their specifics and acting factors. The HDBR, as the name implies, implicates a long (from several weeks to a year) stay in the supine position, the head tilted down by -6° from the horizontal plane. HDBR is the most frequently used ground-based simulation for gravitational unloading of the human body in western countries.
Unlike bed rest, dry immersion provides a unique opportunity to study the physiological effects of the lack of a supporting structure for the body. Dry immersion means immersing the subject into thermoneutral water, while covered with a special elastic free floating waterproof fabric. The subject, surrounded by the tarp and "freely suspended" in the water mass, remains dry. During horizontal immersion, pressure forces are distributed nearly equally around the entire surface of the body (only the head and neck are not entirely supported by water). The absence of mechanical support of specific anatomic zones during immersion creates a state akin to weightlessness called "supportlessness". Physiological changes under DI develop more rapidly and are more profound than under HDBR . This advanced ground-based model is extremely suited to test countermeasures for microgravity-induced deconditioning and physical inactivity-related pathologies.
In 2015, DI facility has been installed at the Space Clinic in Toulouse (France), and a first in Europe three-day dry immersion study was carried out in 12 healthy male volunteers. That study demonstrated an important headward fluid transfer with a significant dilatation of the jugular veins, an increase in venous blood velocities and intracranial pressure, as well as ophthalmological changes consistent with a presumable increase in intracranial pressure at the head at over 20 mmHg (normal values 7 to 15 mmHg), which confirms that dry immersion is a good model to simulate the effects of fluid transfer. In 2019, a second dry-immersion experiment, this time lasting 5 days, was conducted in 18 healthy male volunteers. The goal was to quantify the effect of venoconstrictive thigh cuffs, used for 10 hours/day as a countermeasure, on the time course and extent of DI-induced alterations in body fluids, cephalic circulation, fundus, and brain. These two studies have sparked the interest in the dry immersion model.
Indeed, the European Space Agency (ESA) has decided to include this model in the research programs it promotes on the effects of weightlessness. As a first step, ESA decided to carry out a standardization work like the one done on the bedrest model. ESA tasked a group of European experts to design a first study and the tests that would need to be carried out to better understand and validate the model.
Few studies conducted to date have investigated gender differences in the astronaut population.
The small number of female astronauts may be part of the reason why scientific data are lacking to draw valid conclusions about possible gender differences. However, if women currently constitute only about 12% of astronauts (only 72 women out of 596 astronauts as of December 2021), they are and will be more and more represented in crews. They now constitute 30% of American crews and NASA (US space agency) has announced gender parity for crews on future lunar missions. It is therefore essential to study the physiological changes induced by weightlessness in both sexes, and to develop efficient sex-specific countermeasures. The expert group has therefore concluded that two different studies with the same design should be carried out, one in women and one in men, to obtain a comparable dataset. An immersion period of 5 days was determined to induce the physiological changes they wish to study. A battery of tests has thus been defined by this expert group based on standard tests carried out in bedrest studies (Bedrest Standard Measurements), supplemented by additional tests to further investigate the model and to acquire a better understanding of the time course of the physiological changes in both sexes.
This work has started in 2021 with a first study, conducted in women during a 5-day immersion period (awaiting publication). The next step is to realize a similar set of measurements in men, to standardize the dry immersion model taking into account sex differences.
This study falls within this context and will be the first ESA dry immersion study carried out in men. Its objective is to obtain a standardized dataset for DI in men, which will serve as a basis for the development and evaluation of countermeasures to support future space missions. The main physiological systems will be explored before, during and after the 5 days of immersion through a battery of specific tests and measurements. The results will be analyzed by scientists specializing in each field in order to better understand the dry immersion model, to compare its effects with those of the bedrest model and those of spaceflight. Comparison with results obtained in the female population will be a major part of the analysis. The clinical (adverse effects, comfort of subjects) and operational aspects are also part of the secondary objectives of the study.
- Conditions
- Weightlessness
- Being tested
- Dry immersion
- Keywords
- Microgravity simulation, Models, Weightlessness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dry immersionOther
Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
| Study group | Role | What they receive |
|---|---|---|
| Dry immersion | Experimental | 5 days of dry-immersion Receives: Other: Dry immersion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in orthostatic tolerance
Orthostatic tolerance will be assessed during a Lower Body Negative Pressure test (LBNP test)
Measured: At baseline and five days of 5 days of dry immersion
Change in peak aerobic power (VO2max test)
Exercise capacity wil be assessed by graded cycling on sitting ergometer until exhaustion
Measured: At baseline and the first day of recovery
Change in plasma volume
Plasma volume (L) will be assessed by the carbon monoxide-rebreathing method
Measured: At baseline and five days of dry immersion
Change in fluid shift distribution towards the cardiac and cephalic region
The consequences of the fluid shift on the cardiac and cephalic area will be assessed by quantifying the right and left Jugular veins volumes (mL), as well as the left ventricle diastolic/systolic volumes (mL) by ultrasound.
Measured: At baseline, the first day to quantify the short term effect and the fifth day of dry-immersion to quantify the long term effect of fluid shift
Change in vascular endothelium integrity
Vascular endothelium integrity will be assessed by blood parameters of vascular and endothelial integrity. Global change of endothelial state will be estimated using several biomarkers, including zonulin, cell adhesion molecules (E-selectin, L-selectin, CD146), growth factors (VEGF, VEGFR-1), glycocalyx breakdown products (syndecan-1, hyaluronic acid, heparan sulfate).
Measured: At baseline and during the five days of the dry-immersion period
Change in circadian rhythms of blood pressure
Continuous 24-h recording of systolic and diastolic blood pressure will be performed by a Non Invasive Blood Pressure system (SOMNOtouch™NIBP) designed for ambulatory continuous measurements
Measured: At baseline and during the five days of the dry-immersion period
Change in lower limb veins functions
Venous compliance of lower limbs will be assessed by plethysmography
Measured: At baseline and four days of dry-immersion and one day of recovery
Change in body fluid compartments by bioelectrical impedance analysis
Extracellular, intracellular and total body water will be estimated by bioimpedance
Measured: At baseline and during five days of dry-immersion
Change in muscle strength
Muscle strength will be assessed from single leg isometric maximal voluntary contraction on the knee extensors \& flexors, the plantarflexors and dorsiflexors. The Isometric Torque will be measured in Nm. The peak of the three maximal attempts will be recorded for strength measures
Measured: Before dry immersion and after one day of recovery
Change in muscle fatigue
Muscle fatigability will be assessed during a submaximal isometric knee extension contraction held for 30 seconds at 50% of the baseline Maximal Voluntary Contraction (MVC) value
Measured: Before dry immersion and after one day of recovery
Change in muscle volume at calf level
Muscle dehydration, eventual atrophy and fatty degeneration will be measured by quantitative Dixon MRI sequences at calf level
Measured: At baseline and five days of dry-immersion
Change in contraction time
Contraction time will be assessed during a measurement using the tensiomyography method in the following muscles: vastus lateralis, Gastrocnemius medialis and Biceps femoris of dominant leg / arm.
Measured: At baseline and five days of dry immersion
Change in serum bone formation markers
Change in bone-specific Alkaline Phosphatase (bAP, µg/L) and procollagen type I N-terminal propeptide (P1NP, µg/L) will be assessed by chemiluminescence immunoassay
Measured: At baseline and during the 5 days of dry-immersion
Change in serum bone resorption markers
Change in C-terminal cross-linked telopeptide of type I collagen (CTx, pmol/L) and N-terminal cross-linked telopeptide of type I collagen (NTX, pmol/L) will be assessed by chemiluminescence immunoassay
Measured: At baseline and during the 5 days of dry-immersion
Change in serum cartilage synthesis biomarkers
Change in serum CP II and in human cartilage glycoprotein-39 (YKL-40) concentrations
Measured: At baseline and during the 5 days of dry-immersion
Change in serum cartilage degradation biomarkers
Change in serum Cartilage Oligomeric Matrix Protein (COMP) and fragments or propeptide of type II collagen (C2C, C1,2C, Coll-2-1) concentrations
Measured: At baseline and during the 5 days of dry-immersion
Change in urine cartilage degradation biomarkers
Change in C-telopeptide of type II collagen (CTX-II) and nitrated form of peptide of the α-helical region of type II collagen (Coll-2-1NO2) concentrations
Measured: At baseline and during the 5 days of dry-immersion
Change in Resting Metabolic Rate (RMR)
RMR will be measured by indirect calorimetry technique
Measured: At baseline and 5 days of dry-immersion
Change in nitrogen balance
Nitrogen balance is a measure of nitrogen input minus nitrogen output. Nitrogen intake is calculated with a nutrition software. Protein oxidation measured in the 24-Hour urine collection estimates nitrogen output
Measured: At baseline and 5 days of dry-immersion
Change in fat and lean body mass measured by dual energy x-ray absorptiometry (DEXA)
Dual energy x-ray absorptiometry is a standard clinical technique to assess fat (g) and lean (g) body mass.
Measured: At baseline and 5 days of dry-immersion
Change in glucose tolerance (Oral Glucose Tolerance Test)
Glucose and insulin levels will be measured at baseline (fasting) and 30, 60, 90, and 120 minutes after drinking within 5 min a water solution containing 75 g of glucose
Measured: At baseline and 5 days of dry-immersion
Change in Core temperature
Measured by electronic ingestible temperature capsules (e-Celsius Performance)
Measured: At baseline and during the 5 days of dry immersion
Change in height
Measured in supine and standing position
Measured: Before, during and after the 5 days of dry immersion
Change in mid cerebral artery (MCA) blood flow velocity
Transcranial Doppler measurements
Measured: At baseline and 5 days of dry immersion
Change in mood
Change in mood is assessed using the Profile of Mood States (POMS) questionnaire. POMS questionnaire gives 6 measures of mood:
- Tension/anxiety,
- Depression,
- Anger/hostility
- Dynamism,
- Fatigue,
- Confusion A Total Mood Disturbance (TMD) score is calculated by summing the totals for the negative subscales (tension, depression, fatigue, confusion, anger) and then subtracting the totals for the positive subscale (vigor /esteem-related affect).
Measured: Before, during and after 5 days of dry-immersion
Change in affective states
Positive and Negative Schedule (PANAS) questionnaire will be used to assess the intensity of positive and negative affective states. PANAS self-report questionnaire consists of two 10-item scales to measure both positive and negative affects
Each item is rated on a five-point Likert Scale, ranging from 1 = Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame.
Positive affects: scores can range from 10 - 50 with higher scores representing higher levels of positive affect.
Negative affects: scores can range from 10 - 50 with higher scores representing higher levels of negative affect.
Measured: Before, during and after 5 days of dry-immersion
Change in sleep quality
Pittsburgh Sleep Dairy (PghSD) will be used to assess sleep perceived quality. The PghSD is an instrument with separate components to be completed at bedtime and waketime. The following parameters are registered or assessed:
Bedtime, waketime, sleep latency, wake after sleep onset, total sleep time, mode of awakening and ratings of sleep quality, mood, and alertness on wakening, as well as daytime information on naps, exercise, meals and caffeine, tobacco and medications use.
Measured: Before, during and after 5 days of dry-immersion
Change in psychological state: mental health
General Health Questionnaire-28 (GHQ-28) will be used to assess psychological well-being and capture distress
GHQ-28 gives an overall total score and 4 scores for 4 subscales:
- Somatic symptoms,
- Anxiety/insomnia,
- Social dysfunction,
- Severe depression. Higher scores indicate higher levels of distress
Measured: Before, during and after 5 days of dry-immersion
Change in coping strategies
Brief Cope Questionnaire is designed to measure effective and ineffective ways to cope with a stressful life event, and will be used to assess coping strategies. The Brief Cope is a shortened form (28 items) of the Carver and Scheier COPE inventory.
There are 14 coping strategies. These strategies can be then gathered in two main categories : approach coping and avoidance coping.
Measured: Before, during and after 5 days of dry-immersion
Change in cerebral autoregulation
Transcranial Doppler measurements of mid cerebral artery blood flow velocity will allow to determine cerebral autoregulation
Measured: At baseline and 5 days of dry-immersion
Change in Intra Cranial Pressure (ICP)
ICP changes will be monitored through OtoAcoustic Emissions (OAE)
Measured: At baseline, during and after 5 days of dry-immersion
Change in optic nerve sheath diameter (ONSD) considered as an indirect marker for intracranial pressure (ICP) estimation
The optic nerve sheath diameter (ONSD) variations will be measured by echography
Measured: At baseline, during and after 5 days of dry-immersion
Change in the optic nerve fibers thickness
Thickness of the optic nerve fibers will be measured by Optical Coherence Tomography (OCT)
Measured: At baseline and five days of dry-immersion
Change in intraocular pressure (IOP)
IOP measured by applanation
Measured: At baseline, during and after five days of dry-immersion
Change in visual acuity
Far and near visual acuity are tested uncorrected, or if applicable with own correction with digital acuity system
Measured: At baseline and five days of dry-immersion
Change in visual field
Visual field measured by standard automated perimetry
Measured: At baseline and five days of dry-immersion
Change in the anatomical characteristics of the eye (optical biometry)
Optical biometry measured by partial coherence interferometry
Measured: At baseline and five days of dry-immersion
Change in the central corneal thickness
Central corneal thickness on a single point on the cornea measured by Ultrasonic pachymetry
Measured: At baseline and five days of dry-immersion
Change in the retina by non-mydriatic fundus retinography
Non-mydriatic fundus retinography allows a fundus photography to be taken and thus a color image of the papilla, retinal vessels and macula
Measured: At baseline and five days of dry-immersion
Change in the cornea topography
Cornea topography measured by corneal topography equipment (like Pentacam). The elevation topography according to Scheimpflug principle allows the mapping of the anterior and posterior surface of the cornea.
Measured: At baseline and five days of dry-immersion
Change in cerebral structures and in venous circulation of the brain by MRI
Visualization of cerebral structures and intracranial venous system will be performed by MRI coupled with injection of gadolinium
Measured: At baseline and five days of dry-immersion
Change in walking balance
Walking balance will be assessed by Dynamic Gait Index, specific parameter is: total Score (range 0-24). Higher scores mean a better outcome
Measured: At baseline and the first day of recovery
Change in standing balance
Standing balance will be assessed by posturography eyes open and eyes closed on a platform covered with 12-cm thick medium density foam
Measured: At baseline and the first day of recovery
Change in motion sickness susceptibility
Assessed by the Motion Sickness Susceptibility Questionnaire Short form (MSSQ-Short). MSSQ-Short scores possible range from minimum 0 to maximum 54, the maximum being unlikely. Higher scores means a higher motion sickness susceptibility
Measured: At baseline, during and after 5 days of dry immersion
Change in thrombotic and fibrinolytic processes
Thrombotic and fibrinolytic processes will be assessed by the following four coagulation values:
- plasma levels of tissue factor (TF), the physiological trigger for the coagulation cascade, by using the assay Actichrome Tissue factor ELISA from American Diagnostica (Pfungstadt, Germany); ii) Endogenous thrombin potential, an appropriate method to assess the coagulability of a given plasma sample, by using calibrated automated thrombography (CAT, Thrombinoscope BV, Maastricht, the Netherlands); iii) tissue-Plasminogen activator (tPA), by using the assay IMUBIND tPA ELISA kit from American Diagnostica (Pfungstadt, Germany); iv) thromboelastometry (TEM, coagulation analyzer from Matel Medizintechnik, Graz, Austria), providing a kinetic analysis of the clot formation process and of clot dissolution by the fibrinolytic system.
Measured: Before, during and after 5 days of dry immersion
Change in respiratory volumes
Change in Forced vital capacity (FVC, L), Tidal Volume (TV, L), Inspiratory reserve Volume (IRV, L), Expiratory reserve volume (ERV, L) will be assessed using spirometry
Measured: At baseline, the 1st day of dry immersion and following 5 days of dry immersion
Change in respiratory flows
Change in Forced expiratory volume in 1 second (FEV1, L/s) and in Peak expiratory flow (PEF, L/min), will be assessed using spirometry
Measured: At baseline, the 1st day of dry immersion and following 5 days of dry immersion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2022
- Study start23 Aug 2022
- Primary completion24 Nov 2022
- Study completion24 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for WeightlessnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre National d'Etudes Spatiales
- Sponsor type
- Other government
- Collaborators
- European Space Agency
- Responsible party
- Sponsor
- Investigators
- Rebecca BILLETTE DE VILLEMEUR, MD, Principal investigator, MEDES - IMPS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05493176
- Sponsor's protocol ID
- 22-282
- Other IDs
- 2022-A00881-42
- Acronym
- VIVALDI2
- Status last verified
- Aug 2022
- First submitted
- 29 Jul 2022
- Last updated
- 24 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Navasiolava NM, Custaud MA, Tomilovskaya ES, Larina IM, Mano T, Gauquelin-Koch G, Gharib C, Kozlovskaya IB. Long-term dry immersion: review and prospects. Eur J Appl Physiol. 2011 Jul;111(7):1235-60. doi: 10.1007/s00421-010-1750-x. Epub 2010 Dec 14.
PubMed 21161267De Abreu S, Amirova L, Murphy R, Wallace R, Twomey L, Gauquelin-Koch G, Raverot V, Larcher F, Custaud MA, Navasiolava N. Multi-System Deconditioning in 3-Day Dry Immersion without Daily Raise. Front Physiol. 2017 Oct 13;8:799. doi: 10.3389/fphys.2017.00799. eCollection 2017.
PubMed 29081752Kermorgant M, Leca F, Nasr N, Custaud MA, Geeraerts T, Czosnyka M, Arvanitis DN, Senard JM, Pavy-Le Traon A. Impacts of Simulated Weightlessness by Dry Immersion on Optic Nerve Sheath Diameter and Cerebral Autoregulation. Front Physiol. 2017 Oct 12;8:780. doi: 10.3389/fphys.2017.00780. eCollection 2017.
PubMed 29075198Linossier MT, Amirova LE, Thomas M, Normand M, Bareille MP, Gauquelin-Koch G, Beck A, Costes-Salon MC, Bonneau C, Gharib C, Custaud MA, Vico L. Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines. PLoS One. 2017 Aug 14;12(8):e0182970. doi: 10.1371/journal.pone.0182970. eCollection 2017.
PubMed 28806419Moser D, Bareille MP, Ombergen AV, Hoerl M, D Amico F, Feuerecker M, Dachert C, Matzel S, Robin A, Navasiolava N, Custaud MA, Chouker A; Members of the VivalDI -study and Dry Immersion expert group. Fluid shifts are main drivers for microgravity simulation-induced immune-physiological changes: findings from the VIVALDI studies. NPJ Microgravity. 2026 Feb 16;12(1):15. doi: 10.1038/s41526-025-00555-z.
PubMed 41698943Jacob P, Robin A, Navasiolava N, Custaud MA, Ghislin S, Bareille MP, De Villemeur RB, Antunes I, Van Ombergen A, Gauquelin-Koch G, Frippiat JP. ESA VIVALDI Dry Immersion Microgravity Simulations Induce Increases in Immune Biomarkers Associated With Physical and Psychological Stress, and Sex-Specific Factors. FASEB J. 2025 Sep 15;39(17):e70993. doi: 10.1096/fj.202502198R.
PubMed 40892712
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standardization of the Dry Immersion Model Used as a Ground-based Model to Mimic Weightlessness. Phase 2: a 5-day Dry Immersion Study on 20 Healthy Male Volunteers (VIVALDI2)
- ClinicalTrials.gov ID
- NCT05493176
- Acronym / sponsor ID
- VIVALDI2 / 22-282
- Conditions
- Weightlessness
- Keywords
- Microgravity simulation, Models, Weightlessness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Centre National d'Etudes SpatialesOther government
- Collaborators
- European Space Agency
- Study start
- 23 Aug 2022 (actual)
- Primary completion
- 24 Nov 2022 (actual)
- Study completion
- 24 Nov 2022 (actual)
- First posted
- 9 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dry immersion (DI) is a ground-based model of prolonged conditions of simulated microgravity. Dry immersion involves immersing the subject in water covered with an elastic waterproof fabric. As a result, the immersed subject, who is freely suspended in the water mass, remains dry. Within a relatively short duration, the model can faithfully reproduce most physiological effects of actual microgravity, including centralization of body fluids, support unloading, and hypokinesia.
The main objective of the present study is to investigate the physiological effects of 5 days of dry immersion in 20 healthy male subjects, and to obtain DI-in-Men Reference Dataset. A set of measurements will assess the changes in the cardiovascular, neuro-ophthalmological, hematological, metabolic, sensorimotor, immune, muscle and bone systems.
Detailed description
Space flights have shown the possibilities and limitations of human adaptation to space. For the last 50 years, results have shown that the space environment and microgravity in particular, cause changes that may affect the performance of astronauts. These physiological changes are now better known: prolonged exposure to weightlessness can lead to significant loss of bone and muscle mass, strength, cardiovascular and sensory-motor deconditioning, immune, hormonal and metabolic changes .
Moreover, recently a new suite of physiological adaptations and consequences of space flight has been acknowledged. Indeed, after long flights, some astronauts present persistent ophthalmologic changes, mostly a hyperopic shift, an increase in optic nerve sheath diameter and occasionally a papillary oedema now defined by National Aeronautics and Space Administration (NASA) as Spaceflight-Associated Neuro-ocular Syndrome (SANS). Some of these vision changes remain unresolved for years post-flight. This phenomenon has most likely existed since the beginning of human space flight but is just recently being recognized as a major consequence of adaptation to microgravity.
Overall, spaceflight induces physiological multi-system deconditioning which may impact astronauts' efficiency and create difficulties upon their return to normal gravity. Understanding the underlying mechanisms of these processes and developing efficient countermeasures to prevent, limit or reverse this deconditioning remain important challenges and major priorities for manned space programs.
The space agencies are actively engaged in studying the physiological adaptation to space environment through studies on board the International Space Station (ISS) but also on the ground. Indeed, considering the limited number of flight opportunities, the difficulties related to the performance of in-flight experiments (operational constraints for astronauts, limited capabilities of in-flight biomedical devices), ground-based experiments simulating the effects of weightlessness are used to better understand the mechanisms of physiological adaptation, design and validate the countermeasures. Different methods are used to simulate microgravity on Earth. However, two approaches, -6° head-down bed rest (HDBR) and dry immersion (DI) have provided possibilities for long-term exposures with findings closest to those seen with a weightless state. They produce changes in body composition (including body fluid redistribution), cardiovascular and skeletal muscle characteristics that resemble the effects of microgravity.
The common physiological denominator is the combination of a cephalad shift of body fluids and reduced physical activity. Being similar in their effects on the human body, these models, however, differ in their specifics and acting factors. The HDBR, as the name implies, implicates a long (from several weeks to a year) stay in the supine position, the head tilted down by -6° from the horizontal plane. HDBR is the most frequently used ground-based simulation for gravitational unloading of the human body in western countries.
Unlike bed rest, dry immersion provides a unique opportunity to study the physiological effects of the lack of a supporting structure for the body. Dry immersion means immersing the subject into thermoneutral water, while covered with a special elastic free floating waterproof fabric. The subject, surrounded by the tarp and "freely suspended" in the water mass, remains dry. During horizontal immersion, pressure forces are distributed nearly equally around the entire surface of the body (only the head and neck are not entirely supported by water). The absence of mechanical support of specific anatomic zones during immersion creates a state akin to weightlessness called "supportlessness". Physiological changes under DI develop more rapidly and are more profound than under HDBR . This advanced ground-based model is extremely suited to test countermeasures for microgravity-induced deconditioning and physical inactivity-related pathologies.
In 2015, DI facility has been installed at the Space Clinic in Toulouse (France), and a first in Europe three-day dry immersion study was carried out in 12 healthy male volunteers. That study demonstrated an important headward fluid transfer with a significant dilatation of the jugular veins, an increase in venous blood velocities and intracranial pressure, as well as ophthalmological changes consistent with a presumable increase in intracranial pressure at the head at over 20 mmHg (normal values 7 to 15 mmHg), which confirms that dry immersion is a good model to simulate the effects of fluid transfer. In 2019, a second dry-immersion experiment, this time lasting 5 days, was conducted in 18 healthy male volunteers. The goal was to quantify the effect of venoconstrictive thigh cuffs, used for 10 hours/day as a countermeasure, on the time course and extent of DI-induced alterations in body fluids, cephalic circulation, fundus, and brain. These two studies have sparked the interest in the dry immersion model.
Indeed, the European Space Agency (ESA) has decided to include this model in the research programs it promotes on the effects of weightlessness. As a first step, ESA decided to carry out a standardization work like the one done on the bedrest model. ESA tasked a group of European experts to design a first study and the tests that would need to be carried out to better understand and validate the model.
Few studies conducted to date have investigated gender differences in the astronaut population.
The small number of female astronauts may be part of the reason why scientific data are lacking to draw valid conclusions about possible gender differences. However, if women currently constitute only about 12% of astronauts (only 72 women out of 596 astronauts as of December 2021), they are and will be more and more represented in crews. They now constitute 30% of American crews and NASA (US space agency) has announced gender parity for crews on future lunar missions. It is therefore essential to study the physiological changes induced by weightlessness in both sexes, and to develop efficient sex-specific countermeasures. The expert group has therefore concluded that two different studies with the same design should be carried out, one in women and one in men, to obtain a comparable dataset. An immersion period of 5 days was determined to induce the physiological changes they wish to study. A battery of tests has thus been defined by this expert group based on standard tests carried out in bedrest studies (Bedrest Standard Measurements), supplemented by additional tests to further investigate the model and to acquire a better understanding of the time course of the physiological changes in both sexes.
This work has started in 2021 with a first study, conducted in women during a 5-day immersion period (awaiting publication). The next step is to realize a similar set of measurements in men, to standardize the dry immersion model taking into account sex differences.
This study falls within this context and will be the first ESA dry immersion study carried out in men. Its objective is to obtain a standardized dataset for DI in men, which will serve as a basis for the development and evaluation of countermeasures to support future space missions. The main physiological systems will be explored before, during and after the 5 days of immersion through a battery of specific tests and measurements. The results will be analyzed by scientists specializing in each field in order to better understand the dry immersion model, to compare its effects with those of the bedrest model and those of spaceflight. Comparison with results obtained in the female population will be a major part of the analysis. The clinical (adverse effects, comfort of subjects) and operational aspects are also part of the secondary objectives of the study.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dry immersion | Experimental | Other: Dry immersion5 days of dry-immersion |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Healthy male volunteer (see below the description of medical tests and laboratory analysis performed at the selection visit),
- Age 20 to 40,
- No overweight nor excessive thinness with BMI (weight Kg/ height m2) between 20 and 26,
- Height between 158cm and 185 cm,
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any chronic disease or any acute infectious disease or cardiovascular, neurological, ear, nose, and throat (ENT) (especially orthostatic hypotension and vestibular disorders), orthopaedic or musculoskeletal disorders,
Key exclusion criteria (37 listed)
- Any history or presence of clinically relevant cardiovascular, neurological or ENT (especially orthostatic hypotension and vestibular disorders), any chronic disease; any acute infectious disease, in particular
- Symptomatic orthostatic hypotension whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure (SBP) equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position,
- Cardiac rhythm disorders,
- Hypertension,
- Chronic back pains,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dry immersionSubjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. | Other | Dry immersion |
Primary outcome
Change in orthostatic tolerance
Time frame: At baseline and five days of 5 days of dry immersion
Orthostatic tolerance will be assessed during a Lower Body Negative Pressure test (LBNP test)
Change in peak aerobic power (VO2max test)
Time frame: At baseline and the first day of recovery
Exercise capacity wil be assessed by graded cycling on sitting ergometer until exhaustion
Change in plasma volume
Time frame: At baseline and five days of dry immersion
Plasma volume (L) will be assessed by the carbon monoxide-rebreathing method
Change in fluid shift distribution towards the cardiac and cephalic region
Time frame: At baseline, the first day to quantify the short term effect and the fifth day of dry-immersion to quantify the long term effect of fluid shift
The consequences of the fluid shift on the cardiac and cephalic area will be assessed by quantifying the right and left Jugular veins volumes (mL), as well as the left ventricle diastolic/systolic volumes (mL) by ultrasound.
Change in vascular endothelium integrity
Time frame: At baseline and during the five days of the dry-immersion period
Vascular endothelium integrity will be assessed by blood parameters of vascular and endothelial integrity. Global change of endothelial state will be estimated using several biomarkers, including zonulin, cell adhesion molecules (E-selectin, L-selectin, CD146), growth factors (VEGF, VEGFR-1), glycocalyx breakdown products (syndecan-1, hyaluronic acid, heparan sulfate).
Change in circadian rhythms of blood pressure
Time frame: At baseline and during the five days of the dry-immersion period
Continuous 24-h recording of systolic and diastolic blood pressure will be performed by a Non Invasive Blood Pressure system (SOMNOtouch™NIBP) designed for ambulatory continuous measurements
Change in lower limb veins functions
Time frame: At baseline and four days of dry-immersion and one day of recovery
Venous compliance of lower limbs will be assessed by plethysmography
Change in body fluid compartments by bioelectrical impedance analysis
Time frame: At baseline and during five days of dry-immersion
Extracellular, intracellular and total body water will be estimated by bioimpedance
Change in muscle strength
Time frame: Before dry immersion and after one day of recovery
Muscle strength will be assessed from single leg isometric maximal voluntary contraction on the knee extensors \& flexors, the plantarflexors and dorsiflexors. The Isometric Torque will be measured in Nm. The peak of the three maximal attempts will be recorded for strength measures
Change in muscle fatigue
Time frame: Before dry immersion and after one day of recovery
Muscle fatigability will be assessed during a submaximal isometric knee extension contraction held for 30 seconds at 50% of the baseline Maximal Voluntary Contraction (MVC) value
Change in muscle volume at calf level
Time frame: At baseline and five days of dry-immersion
Muscle dehydration, eventual atrophy and fatty degeneration will be measured by quantitative Dixon MRI sequences at calf level
Change in contraction time
Time frame: At baseline and five days of dry immersion
Contraction time will be assessed during a measurement using the tensiomyography method in the following muscles: vastus lateralis, Gastrocnemius medialis and Biceps femoris of dominant leg / arm.
Change in serum bone formation markers
Time frame: At baseline and during the 5 days of dry-immersion
Change in bone-specific Alkaline Phosphatase (bAP, µg/L) and procollagen type I N-terminal propeptide (P1NP, µg/L) will be assessed by chemiluminescence immunoassay
Change in serum bone resorption markers
Time frame: At baseline and during the 5 days of dry-immersion
Change in C-terminal cross-linked telopeptide of type I collagen (CTx, pmol/L) and N-terminal cross-linked telopeptide of type I collagen (NTX, pmol/L) will be assessed by chemiluminescence immunoassay
Change in serum cartilage synthesis biomarkers
Time frame: At baseline and during the 5 days of dry-immersion
Change in serum CP II and in human cartilage glycoprotein-39 (YKL-40) concentrations
Change in serum cartilage degradation biomarkers
Time frame: At baseline and during the 5 days of dry-immersion
Change in serum Cartilage Oligomeric Matrix Protein (COMP) and fragments or propeptide of type II collagen (C2C, C1,2C, Coll-2-1) concentrations
Change in urine cartilage degradation biomarkers
Time frame: At baseline and during the 5 days of dry-immersion
Change in C-telopeptide of type II collagen (CTX-II) and nitrated form of peptide of the α-helical region of type II collagen (Coll-2-1NO2) concentrations
Change in Resting Metabolic Rate (RMR)
Time frame: At baseline and 5 days of dry-immersion
RMR will be measured by indirect calorimetry technique
Change in nitrogen balance
Time frame: At baseline and 5 days of dry-immersion
Nitrogen balance is a measure of nitrogen input minus nitrogen output. Nitrogen intake is calculated with a nutrition software. Protein oxidation measured in the 24-Hour urine collection estimates nitrogen output
Change in fat and lean body mass measured by dual energy x-ray absorptiometry (DEXA)
Time frame: At baseline and 5 days of dry-immersion
Dual energy x-ray absorptiometry is a standard clinical technique to assess fat (g) and lean (g) body mass.
Change in glucose tolerance (Oral Glucose Tolerance Test)
Time frame: At baseline and 5 days of dry-immersion
Glucose and insulin levels will be measured at baseline (fasting) and 30, 60, 90, and 120 minutes after drinking within 5 min a water solution containing 75 g of glucose
Change in Core temperature
Time frame: At baseline and during the 5 days of dry immersion
Measured by electronic ingestible temperature capsules (e-Celsius Performance)
Change in height
Time frame: Before, during and after the 5 days of dry immersion
Measured in supine and standing position
Change in mid cerebral artery (MCA) blood flow velocity
Time frame: At baseline and 5 days of dry immersion
Transcranial Doppler measurements
Change in mood
Time frame: Before, during and after 5 days of dry-immersion
Change in mood is assessed using the Profile of Mood States (POMS) questionnaire. POMS questionnaire gives 6 measures of mood: 1. Tension/anxiety, 2. Depression, 3. Anger/hostility 4. Dynamism, 5. Fatigue, 6. Confusion A Total Mood Disturbance (TMD) score is calculated by summing the totals for the negative subscales (tension, depression, fatigue, confusion, anger) and then subtracting the totals for the positive subscale (vigor /esteem-related affect).
Change in affective states
Time frame: Before, during and after 5 days of dry-immersion
Positive and Negative Schedule (PANAS) questionnaire will be used to assess the intensity of positive and negative affective states. PANAS self-report questionnaire consists of two 10-item scales to measure both positive and negative affects Each item is rated on a five-point Likert Scale, ranging from 1 = Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame. Positive affects: scores can range from 10 - 50 with higher scores representing higher levels of positive affect. Negative affects: scores can range from 10 - 50 with higher scores representing higher levels of negative affect.
Change in sleep quality
Time frame: Before, during and after 5 days of dry-immersion
Pittsburgh Sleep Dairy (PghSD) will be used to assess sleep perceived quality. The PghSD is an instrument with separate components to be completed at bedtime and waketime. The following parameters are registered or assessed: Bedtime, waketime, sleep latency, wake after sleep onset, total sleep time, mode of awakening and ratings of sleep quality, mood, and alertness on wakening, as well as daytime information on naps, exercise, meals and caffeine, tobacco and medications use.
Change in psychological state: mental health
Time frame: Before, during and after 5 days of dry-immersion
General Health Questionnaire-28 (GHQ-28) will be used to assess psychological well-being and capture distress GHQ-28 gives an overall total score and 4 scores for 4 subscales: * Somatic symptoms, * Anxiety/insomnia, * Social dysfunction, * Severe depression. Higher scores indicate higher levels of distress
Change in coping strategies
Time frame: Before, during and after 5 days of dry-immersion
Brief Cope Questionnaire is designed to measure effective and ineffective ways to cope with a stressful life event, and will be used to assess coping strategies. The Brief Cope is a shortened form (28 items) of the Carver and Scheier COPE inventory. There are 14 coping strategies. These strategies can be then gathered in two main categories : approach coping and avoidance coping.
Change in cerebral autoregulation
Time frame: At baseline and 5 days of dry-immersion
Transcranial Doppler measurements of mid cerebral artery blood flow velocity will allow to determine cerebral autoregulation
Change in Intra Cranial Pressure (ICP)
Time frame: At baseline, during and after 5 days of dry-immersion
ICP changes will be monitored through OtoAcoustic Emissions (OAE)
Change in optic nerve sheath diameter (ONSD) considered as an indirect marker for intracranial pressure (ICP) estimation
Time frame: At baseline, during and after 5 days of dry-immersion
The optic nerve sheath diameter (ONSD) variations will be measured by echography
Change in the optic nerve fibers thickness
Time frame: At baseline and five days of dry-immersion
Thickness of the optic nerve fibers will be measured by Optical Coherence Tomography (OCT)
Change in intraocular pressure (IOP)
Time frame: At baseline, during and after five days of dry-immersion
IOP measured by applanation
Change in visual acuity
Time frame: At baseline and five days of dry-immersion
Far and near visual acuity are tested uncorrected, or if applicable with own correction with digital acuity system
Change in visual field
Time frame: At baseline and five days of dry-immersion
Visual field measured by standard automated perimetry
Change in the anatomical characteristics of the eye (optical biometry)
Time frame: At baseline and five days of dry-immersion
Optical biometry measured by partial coherence interferometry
Change in the central corneal thickness
Time frame: At baseline and five days of dry-immersion
Central corneal thickness on a single point on the cornea measured by Ultrasonic pachymetry
Change in the retina by non-mydriatic fundus retinography
Time frame: At baseline and five days of dry-immersion
Non-mydriatic fundus retinography allows a fundus photography to be taken and thus a color image of the papilla, retinal vessels and macula
Change in the cornea topography
Time frame: At baseline and five days of dry-immersion
Cornea topography measured by corneal topography equipment (like Pentacam). The elevation topography according to Scheimpflug principle allows the mapping of the anterior and posterior surface of the cornea.
Change in cerebral structures and in venous circulation of the brain by MRI
Time frame: At baseline and five days of dry-immersion
Visualization of cerebral structures and intracranial venous system will be performed by MRI coupled with injection of gadolinium
Change in walking balance
Time frame: At baseline and the first day of recovery
Walking balance will be assessed by Dynamic Gait Index, specific parameter is: total Score (range 0-24). Higher scores mean a better outcome
Change in standing balance
Time frame: At baseline and the first day of recovery
Standing balance will be assessed by posturography eyes open and eyes closed on a platform covered with 12-cm thick medium density foam
Change in motion sickness susceptibility
Time frame: At baseline, during and after 5 days of dry immersion
Assessed by the Motion Sickness Susceptibility Questionnaire Short form (MSSQ-Short). MSSQ-Short scores possible range from minimum 0 to maximum 54, the maximum being unlikely. Higher scores means a higher motion sickness susceptibility
Change in thrombotic and fibrinolytic processes
Time frame: Before, during and after 5 days of dry immersion
Thrombotic and fibrinolytic processes will be assessed by the following four coagulation values: i) plasma levels of tissue factor (TF), the physiological trigger for the coagulation cascade, by using the assay Actichrome Tissue factor ELISA from American Diagnostica (Pfungstadt, Germany); ii) Endogenous thrombin potential, an appropriate method to assess the coagulability of a given plasma sample, by using calibrated automated thrombography (CAT, Thrombinoscope BV, Maastricht, the Netherlands); iii) tissue-Plasminogen activator (tPA), by using the assay IMUBIND tPA ELISA kit from American Diagnostica (Pfungstadt, Germany); iv) thromboelastometry (TEM, coagulation analyzer from Matel Medizintechnik, Graz, Austria), providing a kinetic analysis of the clot formation process and of clot dissolution by the fibrinolytic system.
Change in respiratory volumes
Time frame: At baseline, the 1st day of dry immersion and following 5 days of dry immersion
Change in Forced vital capacity (FVC, L), Tidal Volume (TV, L), Inspiratory reserve Volume (IRV, L), Expiratory reserve volume (ERV, L) will be assessed using spirometry
Change in respiratory flows
Time frame: At baseline, the 1st day of dry immersion and following 5 days of dry immersion
Change in Forced expiratory volume in 1 second (FEV1, L/s) and in Peak expiratory flow (PEF, L/min), will be assessed using spirometry
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2023.
- Background: PubMed 21161267Navasiolava NM, Custaud MA, Tomilovskaya ES, Larina IM, Mano T, Gauquelin-Koch G, Gharib C, Kozlovskaya IB. Long-term dry immersion: review and prospects. Eur J Appl Physiol. 2011 Jul;111(7):1235-60. doi: 10.1007/s00421-010-1750-x. Epub 2010 Dec 14.
- Background: PubMed 29081752De Abreu S, Amirova L, Murphy R, Wallace R, Twomey L, Gauquelin-Koch G, Raverot V, Larcher F, Custaud MA, Navasiolava N. Multi-System Deconditioning in 3-Day Dry Immersion without Daily Raise. Front Physiol. 2017 Oct 13;8:799. doi: 10.3389/fphys.2017.00799. eCollection 2017.
- Background: PubMed 29075198Kermorgant M, Leca F, Nasr N, Custaud MA, Geeraerts T, Czosnyka M, Arvanitis DN, Senard JM, Pavy-Le Traon A. Impacts of Simulated Weightlessness by Dry Immersion on Optic Nerve Sheath Diameter and Cerebral Autoregulation. Front Physiol. 2017 Oct 12;8:780. doi: 10.3389/fphys.2017.00780. eCollection 2017.
- Background: PubMed 28806419Linossier MT, Amirova LE, Thomas M, Normand M, Bareille MP, Gauquelin-Koch G, Beck A, Costes-Salon MC, Bonneau C, Gharib C, Custaud MA, Vico L. Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines. PLoS One. 2017 Aug 14;12(8):e0182970. doi: 10.1371/journal.pone.0182970. eCollection 2017.
- Derived from this study: PubMed 41698943Moser D, Bareille MP, Ombergen AV, Hoerl M, D Amico F, Feuerecker M, Dachert C, Matzel S, Robin A, Navasiolava N, Custaud MA, Chouker A; Members of the VivalDI -study and Dry Immersion expert group. Fluid shifts are main drivers for microgravity simulation-induced immune-physiological changes: findings from the VIVALDI studies. NPJ Microgravity. 2026 Feb 16;12(1):15. doi: 10.1038/s41526-025-00555-z.
- Derived from this study: PubMed 40892712Jacob P, Robin A, Navasiolava N, Custaud MA, Ghislin S, Bareille MP, De Villemeur RB, Antunes I, Van Ombergen A, Gauquelin-Koch G, Frippiat JP. ESA VIVALDI Dry Immersion Microgravity Simulations Induce Increases in Immune Biomarkers Associated With Physical and Psychological Stress, and Sex-Specific Factors. FASEB J. 2025 Sep 15;39(17):e70993. doi: 10.1096/fj.202502198R.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rebecca BILLETTE DE VILLEMEUR, MD principal investigator
MEDES - IMPS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dry immersion in people with Weightlessness, run by Centre National d'Etudes Spatiales at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in orthostatic tolerance (time frame: At baseline and five days of 5 days of dry immersion). The study lists 47 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05493176, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2023; AzTrials last refreshed its copy on 7 Nov 2026.